How many insider trades does FilingIQ track for MGNX?

FilingIQ tracks 471 Form 4 insider transactions for MGNX (MACROGENICS INC), covering filings from Apr 15, 2015 onwards. 20 of those were filed in the last 90 days.

Are MGNX insiders net buyers or net sellers?

Across the full Form 4 history for MGNX, 23 transactions (5%) were open-market purchases and 90 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MGNX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MGNX in?

MACROGENICS INC (MGNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $103.74M.

MGNX insider trading

NasdaqGS Healthcare

MACROGENICS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

471

Last 90 days

Buys / sells

5% / 19%

Market cap

$103.74M

About MACROGENICS INC

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Company website: www.macrogenics.com

MGNX insider activity at a glance

FilingIQ has scored 471 insider transactions for MGNX since Apr 15, 2015. The most recent filing in our index is dated Feb 15, 2026.

Across the full history, 23 open-market purchases and 90 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MGNX insider trades is 52.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MGNX trades on FilingIQ Raw filings on SEC EDGAR

Latest MGNX Form 4 filings

Karrels James SVP, CFO and Secretary

S Mar 4, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for MGNX?: FilingIQ tracks 471 Form 4 insider transactions for MGNX (MACROGENICS INC), covering filings from Apr 15, 2015 onwards. 20 of those were filed in the last 90 days.
Are MGNX insiders net buyers or net sellers?: Across the full Form 4 history for MGNX, 23 transactions (5%) were open-market purchases and 90 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MGNX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MGNX in?: MACROGENICS INC (MGNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $103.74M.

Methodology & sources

Every MGNX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.